Abstract
Serious mental illness occurs in 25% of the general population, with many disorders being neurodevelopmental, lifelong, and debilitating. The wide variation and overlap in symptoms across disorders increases the difficulty of research and treatment development. The NIMH Research Domain of Criteria initiative aims to improve our understanding of the molecular and behavioral consequences of specific neurodevelopmental mechanisms across disorders, enabling targeted treatment development. The transcription factor Specificity Protein 4 (SP4) is important for neurodevelopment and is genetically associated with both schizophrenia and bipolar disorder. Reduced Sp4 expression in mice (hypomorphic) reproduces several characteristics of psychiatric disorders. We further tested the utility of Sp4 hypomorphic mice as a model organism relevant to psychiatric disorders by assessing cognitive control plus effort and decision-making aspects of approach motivation using cross-species-relevant tests. Sp4 hypomorphic mice exhibited impaired attention as measured by the 5-Choice Continuous Performance Test, an effect that was attenuated by glycine type-1 transporter (GlyT-1) inhibition. Hypomorphic mice also exhibited reduced motivation to work for a reward and impaired probabilistic learning. These deficits may stem from affected anticipatory reward, analogous to anhedonia in patients with schizophrenia and other psychiatric disorders. Neither positive valence deficit was attenuated by GlyT-1 treatment, suggesting that these and the attentional deficits stem from different underlying mechanisms. Given the association of SP4 gene with schizophrenia and bipolar disorder, the present studies provide support that personalized GlyT-1 inhibition may treat attentional deficits in neuropsychiatric patients with low SP4 levels.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Achat-Mendes C, Nic Dhonnchadha BA, Platt DM, Kantak KM, Spealman RD (2012). Glycine transporter-1 inhibition preceding extinction training inhibits reacquisition of cocaine seeking. Neuropsychopharmacology 37: 2837–2845.
Acheson DT, Twamley EW, Young JW (2013). Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Front Neurosci 7: 103.
Amitai N, Young JW, Higa K, Sharp RF, Geyer MA, Powell SB (2013). Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cogn Affect Behav Neurosci 14: 388–406.
Armstrong K, Williams LE, Heckers S (2012). Revised associative inference paradigm confirms relational memory impairment in schizophrenia. Neuropsychology 26: 451–458.
Bari A, Theobald DE, Caprioli D, Mar AC, Aidoo-Micah A, Dalley JW et al (2010). Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. Neuropsychopharmacology 35: 1290–1301.
Barnes SA, Der-Avakian A, Markou A (2014). Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 24: 744–758.
Bensadoun JC, Brooks SP, Dunnett SB (2004). Free operant and discrete trial performance of mice in the nine-hole box apparatus: validation using amphetamine and scopolamine. Psychopharmacology (Berl) 174: 396–405.
Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP et al (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164: 1593–1602.
Castner SA, Murthy NV, Ridler K, Herdon H, Roberts BM, Weinzimmer DP et al (2014). Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates. Neuropsychopharmacology 39: 2742–2749.
Cuthbert BN (2014). The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 13: 28–35.
Demeter E, Guthrie SK, Taylor SF, Sarter M, Lustig C (2013). Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: evidence from a translational Sustained Attention Task. Schizophr Res 144: 136–141.
Der-Avakian A, D'Souza MS, Pizzagalli DA, Markou A (2013). Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research. Transl Psychiatry 3: e297.
Dowd EC, Barch DM (2010). Anhedonia and emotional experience in schizophrenia: neural and behavioral indicators. Biol Psychiatry 67: 902–911.
Ellenbroek BA, Cools AR (2000). Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11: 223–233.
Frey PW, Colliver JA (1973). Sensitivity and responsibility measures for discrimination learning. Learn Motiv 4: 327–342.
Fuste M, Pinacho R, Melendez-Perez I, Villalmanzo N, Villalta-Gil V, Haro JM et al (2013). Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis. J Psychiatr Res 47: 1608–1614.
Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA (2008). Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull 34: 835–847.
Green DM, Swets JA (1966) Signal Detection Theory and Psychophysics. Wiley & Sons: New York: New York.
Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N et al (2003). Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60: 572–576.
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56: 29–36.
Howe WM, Ji J, Parikh V, Williams S, Mocaer E, Trocme-Thibierge C et al (2010). Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 35: 1391–1401.
Insel TR, Wang PS (2010). Rethinking mental illness. JAMA 303: 1970–1971.
Javitt DC (2012). Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 367–399.
Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M et al (2001). Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4: 385–391.
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234–1236.
Ji B, Wang X, Pinto-Duarte A, Kim M, Caldwell S, Young JW et al (2013). Prolonged ketamine effects in hypomorphic mice: mimicking phenotypes of schizophrenia. PLoS One 8: e66327.
Lido HH, Marston H, Ericson M, Soderpalm B (2012). The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addict Biol 17: 897–907.
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959). Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81: 363–369.
Luck SJ, Ford JM, Sarter M, Lustig C (2011). CNTRICS final biomarker selection: control of Attention. Schizophr Bull 38: 53–61.
Lustig C, Kozak R, Sarter M, Young JW, Robbins TW (2013). CNTRICS final animal model task selection: control of attention. Neurosci Biobehav Rev 37: 2099–2110.
Markou A, Salamone JD, Bussey TJ, Mar AC, Brunner D, Gilmour G et al (2013). Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia. Neurosci Biobehav Rev 37: 2149–2165.
Marston HM (1996). Analysis of cognitive function in animals, the value of SDT. Brain Res Cogn Brain Res 3: 269–277.
McGaughy J, Sarter M (1995). Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands. Psychopharmacology (Berl) 117: 340–357.
McMahon FJ, Insel TR (2012). Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron 74: 773–776.
McNicol D (1972) A Primer of Signal Detection Theory. George Allen & Unwin: London: London.
Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ et al (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66: 1072–1080.
Pinacho R, Villalmanzo N, Lalonde J, Haro JM, Meana JJ, Gill G et al (2011). The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium. Bipolar Disord 13: 474–485.
Priya A, Johar K, Nair B, Wong-Riley MT (2014). Specificity protein 4 (Sp4) regulates the transcription of AMPA receptor subunit GluA2 (Gria2). Biochim Biophys Acta 1843: 1196–1206.
Priya A, Johar K, Wong-Riley MT (2013). Specificity protein 4 functionally regulates the transcription of NMDA receptor subunits GluN1, GluN2A, and GluN2B. Biochim Biophys Acta 1833: 2745–2756.
Ragland JD, Blumenfeld RS, Ramsay IS, Yonelinas A, Yoon J, Solomon M et al (2012a). Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia. Neuroimage 59: 1719–1726.
Ragland JD, Cohen NJ, Cools R, Frank MJ, Hannula DE, Ranganath C (2012b). CNTRICS imaging biomarkers final task selection: Long-term memory and reinforcement learning. Schizophr Bull 38: 62–72.
Ramos B, Gaudilliere B, Bonni A, Gill G (2007). Transcription factor Sp4 regulates dendritic patterning during cerebellar maturation. Proc Natl Acad Sci U S A 104: 9882–9887.
Riccio CA, Reynolds CR, Lowe P, Moore JJ (2002). The continuous performance test: a window on the neural substrates for attention? Arch Clin Neuropsychol 17: 235–272.
Sahgal A (1987). Some limitations of indices derived from signal detection theory: evaluation of an alternative index for measuring bias in memory tasks. Psychopharmacology (Berl) 91: 517–520.
Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA et al (2011). Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 16: 193–201.
Sun X, Pinacho R, Saia G, Punko D, Meana JJ, Ramos B et al (2014). Transcription factor Sp4 regulates expression of nervous wreck 2 to control NMDAR1 levels and dendrite patterning. Dev Neurobiol 75: 93–108.
Supp DM, Witte DP, Branford WW, Smith EP, Potter SS (1996). Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility. Dev Biol 176: 284–299.
Tam GW, van de Lagemaat LN, Redon R, Strathdee KE, Croning MD, Malloy MP et al (2010). Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem Soc Trans 38: 445–451.
van Enkhuizen J, Acheson D, Risbrough V, Drummond S, Geyer MA, Young JW (2013). Sleep deprivation impairs performance in the 5-choice continuous performance test: Similarities between humans and mice. Behav Brain Res 261C: 40–48.
Waltz JA, Frank MJ, Wiecki TV, Gold JM (2011). Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology 25: 86–97.
Waltz JA, Gold JM (2007). Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr Res 93: 296–303.
Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA et al (2014). Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull 40: 1328–1337.
Xu TX, Ma Q, Spealman RD, Yao WD (2010). Amphetamine modulation of long-term potentiation in the prefrontal cortex: dose dependency, monoaminergic contributions, and paradoxical rescue in hyperdopaminergic mutant. J Neurochem 115: 1643–1654.
Young J, Geyer M (2015). Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol 29: 178–196.
Young J, Kamenski M, Geyer M (2012). Delayed 'eureka' of alpha 7 nicotinic acetylcholine receptor knockout mice in a probabilistic reversal learning paradigm. Schizophr Res 136: S361.
Young JW, Geyer MA (2010). Action of modafinil-increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry 67: 784–787.
Young JW, Geyer MA, Rissling AJ, Sharp RF, Eyler LT, Asgaard GL et al (2013a). Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Transl Psychiatry 3: e324.
Young JW, Jentsch JD, Bussey TJ, Wallace TL, Hutcheson DM (2013b). Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev 37: 2181–2193.
Young JW, Light GA, Marston HM, Sharp R, Geyer MA (2009). The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One 4: e4227.
Young JW, Meves JM, Geyer MA (2013c). Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res 240: 119–133.
Young JW, Meves JM, Tarantino IS, Caldwell S, Geyer MA (2011). Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav 10: 720–733.
Young JW, Zhou X, Geyer MA (2010) Animal models of schizophrenia. In: Swerdlow NR (ed) Behavioral Neurobiology of Schiozphrenia and Its Treatment. Springer: Berlin: Berlin pp. 391–433.
Zhou X, Long JM, Geyer MA, Masliah E, Kelsoe JR, Wynshaw-Boris A et al (2005). Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Mol Psychiatry 10: 393–406.
Zhou X, Nie Z, Roberts A, Zhang D, Sebat J, Malhotra D et al (2010). Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet 19: 3797–3805.
Zhou X, Qyang Y, Kelsoe JR, Masliah E, Geyer MA (2007). Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Behav 6: 269–276.
Zhou X, Tang W, Greenwood TA, Guo S, He L, Geyer MA et al (2009). Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One 4: e5196.
Acknowledgements
We thank Richard Sharp and Mahálah Buell for their support. Specifically, these studies were supported by NIH grants R01-MH073991, R01-MH104344, and R21-MH101579, as well as by the Brain and Behavior Research Foundation and by pilot funding from the UCSD Clinical Translational Research Initiative.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Rights and permissions
About this article
Cite this article
Young, J., Kamenski, M., Higa, K. et al. GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacol 40, 2715–2726 (2015). https://doi.org/10.1038/npp.2015.120
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2015.120
This article is cited by
-
A low-cost open-source 5-choice operant box system optimized for electrophysiology and optophysiology in mice
Scientific Reports (2021)
-
Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes
Molecular Neurobiology (2021)
-
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management
Molecular Neurobiology (2020)
-
Hippocampal–prefrontal coherence mediates working memory and selective attention at distinct frequency bands and provides a causal link between schizophrenia and its risk gene GRIA1
Translational Psychiatry (2019)
-
Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia
Translational Psychiatry (2018)
